Association of activated transcription factor nuclear factor κB with chemoradiation resistance and poor outcome in esophageal carcinoma

Journal of Clinical Oncology

Volumn 24, Issue 5, 2006, Pages 748-754

  Izzo, Julie G ^a   Malhotra, Usha ^a   Wu, Tsung Teh ^a   Ensor, Joe ^a   Luthra, Rajyalakshmi ^a   Lee, Jeffrey H ^a   Swisher, Stephen G ^a   Liao, Zhongxing ^a   Chao, K S Clifford ^a   Hittelman, Walter N ^a   Aggarwal, Bharat B ^a   Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; TAXOID;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; ESOPHAGUS CARCINOMA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; TRANSCRIPTION INITIATION; TREATMENT OUTCOME; BIOSYNTHESIS; CANCER INVASION; CANCER STAGING; CARCINOMA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; ESOPHAGUS TUMOR; GENE EXPRESSION PROFILING; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROGNOSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NF-KAPPA B; PROGNOSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 33644853585     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.8810     Document Type: Article

References (45)

1. Jemal A, Murray T, Ward E, et al: Cancer Statistics 2005. CA Cancer J Clin 55:10-30, 2005
2. Hofstetter W, Swisher SG, Correa AM, et al: Treatment outcomes of resected esophageal cancer. Ann Surg 236:376-384, 2002
3. Kelsen DP, Ginsberg R, Pajak TF, et al: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339:1979-1984, 1998
4. Al Sarraf M, Martz K, Herskovic A, et al: Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: An intergroup study. J Clin Oncol 15:277-284, 1997
5. Bosset JF, Gignoux M, Triboulet JP, et al: Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 337:161-167, 1997
6. Cooper JS, Guo MD, Herskovic A, et al: Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281:1623-1627, 1999
7. Malthaner RA, Wong RK, Rumble RB, et al: Neoadjuvant or adjuvant therapy for resectable esophageal cancer: A systematic review and meta-analysis. BMC Med 2:35-40, 2004
8. Stahl M, Stuschke M, Lehmann N, et al: Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23:2310-2317, 2005
9. Kaklamanos IG, Walker GR, Ferry K, et al: Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: A meta-analysis of randomized clinical trials. Ann Surg Oncol 10:754-761, 2003
10. Berger AC, Farma J, Scott WJ, et al: Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 23:4330-4337, 2005
11. Jin J, Liao Z, Zhang Z, et al: Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 60:427-436, 2004
12. Rahatgi P, Swisher SG, Correa AM, et al: Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer (in press)
13. Chirieac LR, Swisher SG, Ajani JA, et al: Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 103:1347-1355, 2005
14. Swisher SG, Hofstetter W, Wu TT, et al: Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg 241:810-817, 2005
15. Aloia TA, Harpole DH Jr, Reed CE, et al: Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann Thorac Surg 72:859-866, 2001
16. Rahatgi P, Swisher SG, Correa AM, et al: Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherpay for carcinoma of the esophagus. Cancer (in press)
17. Aggarwal BB: Nuclear factor-kappa B: The enemy within. Cancer Cell 6:203-208, 2004
18. Hayden MS, Ghosh S: Signaling to NF-kappaB. Genes Dev 18:2195-2224, 2004
19. Balkwill F: Cancer and the chemokine network. Nat Rev Cancer 4:540-550, 2004
20. Greten FR, Eckmann L, Greten TF, et al: IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:285-296, 2004
21. Karin M, Cao Y, Greten FR, et al: NF-kappaB in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2:301-310, 2002
22. Luthra R, Wu TT, Luthra MG, et al: Gene expression profiling of localized esophageal carcinomas: Association with pathologic response to preoperative chemoradiation. J Clin Oncol 24:259-267, 2006
23. Zeng F, Schultz RM: RNA transcript profiling during zygotic gene activation in the preimplantation mouse embryo. Dev Biol 283:40-57, 2005
24. Siripurapu V, Meth J, Kobayashi N, et al: DBC2 significantly influences cell-cycle, apoptosis, cytoskeleton and membrane-trafficking pathways. J. Mol Biol 346:83-89, 2005
25. Sharma RA, Euden SA, Platton SL, et al: Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. Clin Cancer Res 10:6847-6854, 2004
26. Cheng AL, Hsu CH, Lin JK, et al: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21:2895-2900, 2001
27. Aggarwal BB, Kumar A, Bharti AC: Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res 23:363-398, 2003
28. Izzo JG, Papadimitrakopoulou VA, Liu DD, et al: Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst 95:198-205, 2003
29. Konturek PC, Nikiforuk A, Kania J, et al: Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: A possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors. Dig Dis Sci 49:1075-1083, 2004
30. Abdel-Latif MM, O'Riordan J, Windle HJ, et al: NF-kappaB activation in esophageal adenocarcinoma: Relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg 239:491-500, 2004
31. Bachelder RE, Yoon SO, Franci C, et al: Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: Implications for the epithelial-mesenchymal transition. J Cell Biol 168:29-33, 2005
32. Huber MA, Azoitei N, Baumann B, et al: NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 114:569-581, 2004
33. Hu MC, Lee DF, Xia W, et al: IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOX03a. Cell 117:225-237, 2004
34. Cusack JC Jr, Liu R, Baldwin AS: Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation. Cancer Res 60:2323-2330, 2000
35. Das KC, White CW: Activation of NF-kappaB by antineoplastic agents: Role of protein kinase C. J Biol Chem 272:14914-14920, 1997
36. Bottero V, Busuttil V, Loubat A, et al: Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: A brake to apoptosis in HeLa human carcinoma cells. Cancer Res 61:7785-7791, 2001
37. Bourgarel-Rey V, Vallee S, Rimet O, et al: Involvement of nuclear factor kappaB in c-Myc induction by tubulin polymerization inhibitors. Mol Pharmacol 59:1165-1170, 2001
38. Rosette C, Karin M: Cytoskeletal control of gene expression: Depolymerization of microtubules activates NF-kappa B. J Cell Biol 128:1111-1119, 1995
39. Fahy BN, Schlieman MG, Virudachalam S, et al: Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: Implications for therapy in pancreatic cancer. J Am Coll Surg 198:591-599, 2004
40. Russell JS, Tofilon PJ: Radiation-induced activation of nuclear factor-kappaB involves selective degradation of plasma membrane-associated I(kappa)B(alpha). Mol Biol Cell 13:3431-3440, 2002
41. Sanchez-Perez I, Benitah SA, Martinez-Gomariz M, et al: Cell stress and MEKK1-mediated c-Jun activation modulate NFkappaB activity and cell viability. Mol Biol Cell 13:2933-2945, 2002
42. Brach MA, Hass R, Sherman ML, et al: Ionizing radiation induces expression and binding activity of the nuclear factor kappa B. J Clin Invest 88:691-695, 1991
43. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, et al: Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 20:7597-7609, 2001
44. Tergaonkar V, Pando M, Vafa O, et al: p53 stabilization is decreased upon NFkappaB activation: A role for NFkappaB in acquisition of resistance to chemotherapy. Cancer Cell 1:493-503, 2002
45. Tergaonkar V, Bottero V, Ikawa M, et al: IkappaB kinase-independent IkappaBalpha degradation pathway: Functional NF-kappaB activity and implications for cancer therapy. Mol Cell Biol 23:8070-8083, 2003